glp-1 after tummy tuck Medications Drive Surge in Tucks and Body Contouring Surgeries Amid Weight Loss Trends ✨ Transformation Goals! ✨ Our

Description

Currently, approximately 40 million patients in the US have insurance coverage for Wegovy--30 million via commercial health insurance, and the remaining through Medicaid

[DOI] [PubMed] [Google Scholar] 46.Trapp C.M., Censani M

The parallel is not exact, but it provides a plausible biological explanation for why some patients experience reduced sexual desire on GLP-1 therapy

The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear